Marker Therapeutics
MRKR
36 hedge funds and large institutions have $6.03M invested in Marker Therapeutics in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 5 closing their positions.
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
95% more capital invested
Capital invested by funds: $3.09M → $6.03M (+$2.94M)
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
13% more funds holding
Funds holding: 32 → 36 (+4)
2.45% less ownership
Funds ownership: 26.71% → 24.26% (-2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$191K |
| 2 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$169K |
| 3 |
Two Sigma Investments
New York
|
+$69.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$66.6K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$52.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGIA
Torrey Growth & Income Advisors
Del Mar,
California
|
-$46.4K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$42.5K |
| 3 |
VF
Virtu Financial
New York
|
-$25K |
| 4 |
Citigroup
New York
|
-$10.5K |
| 5 |
I
INVST
Indianapolis,
Indiana
|
-$2.27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
BlackRock
New York
| $1.48K | – | – | – |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $1.06K | +$809 | +714 | New |
|
|
UFPG
28
United Financial Planning Group
Hauppauge,
New York
| $373 | +$283 | +250 | New |
|
29
Wells Fargo
San Francisco,
California
| $361 | – | – | – |
|
|
SS
30
SBI Securities
Tokyo,
Japan
| $302 | – | – | – |
|
31
Group One Trading
Chicago,
Illinois
| $265 | – | – | – |
|
|
HNB
32
Hilltop National Bank
Casper,
Wyoming
| $109 | – | – | – |
|
33
BNP Paribas Financial Markets
Paris,
France
| $34 | – | – | – |
|
34
JP Morgan Chase
New York
| $34 | – | – | – |
|
35
Morgan Stanley
New York
| $22 | -$505 | -446 | -97% |
|
|
36
Citigroup
New York
| $9 | -$10.5K | -9,270 | -100% |
|
|
TGIA
37
Torrey Growth & Income Advisors
Del Mar,
California
| – | -$46.4K | -51,984 | Closed |
|
|
TSS
38
Two Sigma Securities
New York
| – | -$42.5K | -47,603 | Closed |
|
|
VF
39
Virtu Financial
New York
| – | -$25K | -28,329 | Closed |
|
40
Fidelity Investments
Boston,
Massachusetts
| – | -$134 | -150 | Closed |
|
|
VCM
41
Versant Capital Management
Phoenix,
Arizona
| – | -$13 | -15 | Closed |
|
MRKR Hedge Fund Activity: Q4 2025 in Review
36 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q4 2025, worth a combined $6.03M — up 95% from $3.09M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new MRKR positions and 5 closed out — a net gain of 4 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was UBS Group, adding an estimated $191K. The largest seller was Torrey Growth & Income Advisors, exiting entirely with an estimated $46.4K sold.
- 36 institutional investors held Marker Therapeutics (MRKR) as of Q4 2025, up from 32 in Q3 2025.
- Funds reported $6.03M of Marker Therapeutics stock for Q4 2025, up 95% quarter-over-quarter.
- 9 funds opened new Marker Therapeutics positions in Q4 2025 and 5 closed out, a net change of +4 holders.
- The largest Marker Therapeutics buyer in Q4 2025 was UBS Group, an estimated $191K added.
- The largest Marker Therapeutics seller in Q4 2025 was Torrey Growth & Income Advisors, an estimated $46.4K sold.
Based on aggregated 13F filings for Q4 2025.